title: Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.
abstract: OBJECTIVE
  The phase III GO-FORWARD study examined the efficacy and safety of golimumab in patients with active rheumatoid arthritis (RA) despite methotrexate therapy.
  
  
  METHODS
  Patients were randomly assigned in a 3 : 3 : 2 : 2 ratio to receive placebo injections plus methotrexate capsules (group 1, n = 133), golimumab 100 mg injections plus placebo capsules (group 2, n = 133), golimumab 50 mg injections plus methotrexate capsules (group 3, n = 89), or golimumab 100 mg injections plus methotrexate capsules (group 4, n = 89). Injections were administered subcutaneously every 4 weeks. The co-primary endpoints were the proportion of patients with 20% or greater improvement in the American College of Rheumatology criteria (ACR20) at week 14 and the change from baseline in the health assessment questionnaire-disability index (HAQ-DI) score at week 24.
  
  
  RESULTS
  The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p = 0.059) in the golimumab 100 mg plus placebo group, 55.1% (p = 0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p = 0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively. During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.
  
  
  CONCLUSIONS
  The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function.
authors.affiliation: University of Toronto and Mount Sinai Hospital, Ontario, Canada. edkeystone@mtsinai.on.ca
authors.forename: E C
authors.initials: EC
authors.lastname: Keystone
authors.forename: M C
authors.initials: MC
authors.lastname: Genovese
authors.forename: L
authors.initials: L
authors.lastname: Klareskog
authors.forename: E C
authors.initials: EC
authors.lastname: Hsia
authors.forename: S T
authors.initials: ST
authors.lastname: Hall
authors.forename: P C
authors.initials: PC
authors.lastname: Miranda
authors.forename: J
authors.initials: J
authors.lastname: Pazdur
authors.forename: S-C
authors.initials: SC
authors.lastname: Bae
authors.forename: W
authors.initials: W
authors.lastname: Palmer
authors.forename: J
authors.initials: J
authors.lastname: Zrubek
authors.forename: M
authors.initials: M
authors.lastname: Wiekowski
authors.forename: S
authors.initials: S
authors.lastname: Visvanathan
authors.forename: Z
authors.initials: Z
authors.lastname: Wu
authors.forename: M U
authors.initials: MU
authors.lastname: Rahman
mesh_terms: D000208:Acute Disease; D000328:Adult; D000704:Analysis of Variance; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology; D001424:Bacterial Infections / Q000150:complications; D016009:Chi-Square Distribution; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab; D008727:Methotrexate